Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Treilleux

Showing results (171-180 of 186) with videos related to

Pageof 19
Sort By:
BMC Cancer|May 11, 2022
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancerFlora Nguyen Van Long, Audrey Lardy-Cleaud, Dimitri Carène, et al.
Cancer Research Communications|June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian CarcinosarcomasAnne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Annales De Pathologie|November 9, 2010
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Jean-Pierre Bellocq, et al.
Cell Death and Differentiation|August 26, 2023
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitorBenjamin Ducarouge, Anna-Rita Redavid, Camille Victoor, et al.
Annales De Pathologie|July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie|December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Annales De Pathologie|December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 19

Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
BMC Cancer|May 11, 2022
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancerFlora Nguyen Van Long, Audrey Lardy-Cleaud, Dimitri Carène, et al.
Cancer Research Communications|June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian CarcinosarcomasAnne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Annales De Pathologie|November 9, 2010
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Jean-Pierre Bellocq, et al.
Cell Death and Differentiation|August 26, 2023
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitorBenjamin Ducarouge, Anna-Rita Redavid, Camille Victoor, et al.
Annales De Pathologie|July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie|December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Annales De Pathologie|December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 19